FIELD: biotechnology.
SUBSTANCE: invention can be used in medical practice. The invention discloses an immunocytokine for activation of the human interleukin 10 receptor (IL-10R). The invention also relates to nucleic acids encoding the specified immunocytokine, expression vectors, host cells and methods of their production, methods of producing the immunocytokine, as well as pharmaceutical compositions containing the above immunocytokine.
EFFECT: invention can be used in the treatment of various oncological diseases.
34 cl, 14 ex, 2 tbl, 15 dwg
Title | Year | Author | Number |
---|---|---|---|
IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
Authors
Dates
2023-12-28—Published
2020-12-10—Filed